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Abstract
Ketamine is a phencyclidine derivative and N-methyl-D-aspartate receptor antag-
onist, widely popular as a dissociative anesthetic. Its use as an anesthetic in humans 
was progressively fallen out due to its associated adverse effects and the emergence 
of newer and safer anesthetics. In recent few decades, various reports related to its 
efficacy in the treatment of resistant depression with anti-suicidal potential draw 
significant attention from researchers around the globe. The rapid clinical effect of 
ketamine within hours as compared to traditional antidepressants that take several 
weeks makes it a hot topic in antidepressant research. Studies conducted in the recent 
past suggest its mechanism of action through glutamate modulation via receptors like 
NMDA, AMPA as well as downregulation of BDNF etc. This chapter will shed light 
on the various mechanisms of ketamine related to antidepressant activity. Along with 
that its pharmacokinetics, toxicology and ongoing clinical trials will also be discussed.
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1. Introduction
From last few decades with rapid development and modernization, significant 
improvements in the lifestyle of humans has been observed but with pros there are 
associated cons and so is major depressive disorder (MDD) which is affecting teen-
agers to adults and majorly observed in young working professionals. It is emerging 
as major contributor in global disease burden and reported as the second leading 
causes for disability [1]. According to the study conducted by mental health in 
Canada, MDD has lifetime prevalence of 11.3% [2]. Besides being a major challenge 
for healthcare system its pathophysiology is still not uncovered completely. One 
hypothesis based on monoamines suggest that it may resulted from functional defi-
ciency of neurotransmitters named serotonin and/or noradrenaline which is widely 
utilized for categorization of antidepressant drugs [3]. But conflict is also standstill 
with the time frame of the effect and dose administration as clinical symptoms are 
observed after several weeks from the onset of therapy and only half are noted to 
have actual clinical response [4–7]. Apart from that one-third patients suffers from 
treatment resistant depression (TRD) that are nonresponsive to currently approved 
medications [8]. Non-responsiveness of currently available therapy especially for 
TRD arise the emergency need of more effective and safer antidepressant therapy.
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Ketamine is a phencyclidine derivative and N-methyl-D-aspartate (NMDA) 
receptor antagonist, widely popular as a dissociative anesthetic. Ketamine was first 
reported for its efficacy in depression in year 2000, when sub-anesthetic intrave-
nous dose of ketamine rapidly reduced the symptoms of MDD and effect continued 
up to 72 hours [9]. Taking lead from this, further clinical trials were conducted 
which showcase its efficacy in TRD patients with 60–70% response rate [10–14]. 
Onset of action was reported within 2–4 hours and last for 1 week with singe infu-
sion while repeated infusions have effect up to 18–19 days. Clinical data also suggest 
the responsiveness of ketamine up to 44% on patients with comorbidities and ultra-
resistant depression [15, 16]. In addition to this ketamine has been reported for 
its anti-suicidal and anti-anhedonic properties [14, 17, 18]. All this reports points 
toward the different mechanism of ketamine form traditional antidepressants.
2. Basic chemistry, pharmacology and pharmacokinetics of ketamine
Recently discovered antidepressant and anti-suicidal action of ketamine sig-
nificantly attracted the researchers working in the field of psychiatry [9, 11, 19]. 
Ketamine is a phencyclidine derivative and a mixture of R(−) and S(+) enantiomers. 
Both R(−) and S(+) enantiomers has been explored widely and it was observed 
that S(+) enantiomer has higher potency than R(−) enantiomer (R-ketamine) 
for phencyclidine site on glutamate NMDA receptor along with stronger analgesic 
activity [20–24]. Inspired form these outputs, S(+) enantiomer also known as 
esketamine is now under investigations for antidepressant potential [25]. However 
Figure 1. 
General layout of metabolic pathway of ketamine showcasing stereoseletive metabolism through various 
cytochrome P450 enzymes.
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conflict between these two is also exist with the side effects profile of both enan-
tiomers related to dissociation, psychoses and cognition [26]. Reports suggest the 
rapid onset of antidepressant effects with R-ketamine but higher side effects than 
esketamine [27–34]. Ketamine undergo metabolism through CYP2B6- and CYP3A4-
mediated N-demethylation resulting norketamine which further catabolized into 
hydroxynorketamines (HNKs) and dehyronorketamine (Figure 1). Investigations 
was also carried out on metabolites of ketamine. 2R,6R-HNK has been observed 
to have antidepressant like efficacy with nil side effects on rat models while sev-
eral contradictory reports are also available [35–43]. Specifically, metabolite of 
esketamine i.e. S-norketamine showed antidepressant like properties with lesser 
side effects as with esketamine [44]. When talk about bioavailability, ketamine has 
varying bioavailability profile with different routes i.e. 100% with intravenous, 45% 
with intranasal, 30% with sublingual, 20% with oral, 93% with intramuscular while 
30% with rectal route [24, 30, 44].
3.  Overview of the status of clinical trials with ketamine and its 
enantiomers
Report on antidepressant efficacy of ketamine by Berman group in 2000 [9]  
initiated series of studies related to antidepressant activity of ketamine all around 
the globe. Multiple meta-analysis now established the candidature of ketamine 
against major depressive episodes in both bipolar as well as unipolar depression 
while efficacy was higher in unipolar as compared to bipolar depression [45–50]. In 
addition to this, numerous studies reported its effect last up to a week only for uni-
polar while it is up to 3–4 days in case of bipolar depression [46, 47, 49]. Randomized 
Controlled trials (RCT) exist in which effect of repeated infusions of ketamine for 
depression is studied but there is still lack of long term trial [51–53]. Studies on dif-
ferent routes of administration were also conducted that majorly include intranasal, 
sublingual and intramuscular [54–57]. In fact intranasal esketaminerecently got 
FDA clearance for TRD which was based on three acute-phase and two maintenance 
phase studies. These acute studies were conducted on severely depressed patients 
[58]. Maintenance trials were conducted up to 88 weeks where patient was adminis-
tered esketamine weekly or every second week showcase reduced after relapse risk 
and also assured safety up to a year [59, 60]. A phase three trial consisted of 200 
patients suggest the significant improvements in depression with ketamine adjuvant 
to an antidepressant [61]. There is another 5 year ongoing trial by Janssen for safety 
[62]. Keeping in view the antidepressant efficacy if R-ketamine, a phase I trial was 
started by Perception Pharmaceuticals but results are not processed yet [28].
4. Mechanistic insight into the antidepressant activity of ketamine
4.1 AMPA, BDNF and mTOR
Glutamate is one of the major excitatory neurotransmitters in central nervous 
system of human body that mainly acts on NMDA, ionotropic α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (co-localized 
with NMDA) and metabotropic glutamate receptors. Glutamate activates AMPA 
receptors at synaptic cleft, which permit the entry of sodium ions into postsyn-
aptic membrane. Entry of sodium ions results in depolarization of postsynaptic 
membrane that cause removal of NMDA receptor channel voltage-dependent 
magnesium ion block that activate NMDA receptor which allow the entry of 
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sodium as well as calcium ions. Ketamine is a well-established non-competitive 
type NMDA receptor antagonist. Brain-derived neurotrophic factor (BDNF) and 
mTOR are two major proteins that are suspected to be involved in mechanistic 
window of ketamine. BDNF is a growth factor protein in central nervous system 
that promote neurogenesis and synaptogenesis along with support in survival of 
existing neurons. On the other hand, mTOR is suggested to have major role in 
neuronal development and circuit formation. mTOR further made two sub com-
plexes known as mTOR complex 1 (mTORC1) and mTOR, from which mTORC1 
is a target of ketamine [63, 64].
It has been observe that glutamatergic neurotransmission is deregulated in 
MDD and enhanced levels of glutamate levels in serum and plasma were observed 
in patient’s dealing with MDD that why plasma glutamate levels are directly corre-
lated with severity of depression [65–68]. Enhanced glutamate cause by loss of glial 
cells in MDD increases extra synaptic glutamate levels that suppressglutamatergic 
neurotransmission via activation of metabotropic glutamate receptor 2 (mGluR2) 
autoreceptors. A study suggest that change in depression symptoms by non-ket-
amine NMDA receptor antagonists like traxoprodil, lanicemine and rapastinel was 
much lower ass compared to ketamine [34, 69–71]. Ketamine good antagonistic 
activity for NMDA receptors present on γ-aminobutyric acid (GABA) that prevent 
activation of GABA interneurons resulting in downstream disinhibition of gluta-
matergic neurons that cause glutamate surge. Elevated levels of glutamate initiates 
activation of postsynaptic AMPA receptors that potentiate BDNF andmTORC1 sig-
naling pathways. Ketamine demonstrated activate glutamate release and transmis-
sion in rat prefrontal cortex (RPC) [72]. Ketamine was also observed to enhance 
AMPA-evoked electrophysiological responses in the rat hippocampus and medial 
PFC pointing toward the involvement of ketamine in AMPA receptor transmission 
[73–77]. In a mouse model, ketamine was observed to increase the expression levels 
of two subunits of AMPA receptor known as GluA1 and GluA2 [34, 78].
Increased levels of BDNF and mTOR in rat hippocampus were observed within 
30 minutes of treatment with ketamine [73, 79, 80]. Important to mention here 
that analgesic tramadol enhanced the effect of ketamine on force swim test along 
with upregulation of mTOR in the PFC and hippocampus of rat [81]. It is interest-
ing to observe that increased BDNF and mTOR levels in hippocampal and RFC are 
controlled by AMPA because in a study treatment with AMPA receptor antagonist 
increased forced-swim test immobility time with reduced levels of BDNF and mTOR 
while with agonist immobility time reduced along with increased levels of both BDNF 
and mTOR [82]. Reports were also observed that suggest the nullification of antide-
pressant activity of ketamine with pre-treatment of rapamycin an mTORC1 inhibi-
tor [83].
Numerous reports are present in the literature suggesting the possibility of 
ketamine’s antidepressant activity via BDNF. No antidepressant activity was 
observed on treatment of ketamine in genetically modified mice lacking BDNF 
[73]. It is proposed that antagonism of NMDA through ketamine deactivates the 
eukaryotic elongation of factor 2 (eEF2) kinase that de-supress the translation 
of BDNF. Mice having Val66Met single-nucleotide polymorphism in BDNF gene 
showed impairment in BDNF release and mRNA trafficking. Administration of 
ketamine in these mice showed reduced antidepressant activity [84]. Reversal of 
anhedonicbehaviour with ketamine was observed in rats with chronic mild stress 
along with complete restoration of dendritic atrophy and dendritiv BDNF mRNA 
trafficking [85]. In social defeat stress model of mice, ketamine lessen reduction in 
BDNF, spine density of dendrites, synaptogenesis markers (GluA1 and PSD-95) in 
PFC, CA3 and dentate gyrus region of hippocampus at 8th day of treatment [86]. 
Elevated levels of BDNF were supposed to be associated with the lower severity 
5
Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future…
DOI: http://dx.doi.org/10.5772/intechopen.99765
of depression like symptoms on rating scale [87, 88]. A study carried out on three 
depressed patients, suggest their response to ketamine and have increased levels of 
plasma mTOR expression and eEF2 phosphorylaton [89]. It is worth to note that in 
a trial conducted on 20 patients, pre-treatment with rapamycin tripled the response 
rate after 2 weeks from treatment thus may be due to targeting of rapamycin on 
neuroinflammation through its immunisupressant activity or may be due to promo-
tion of haemostatsis of synaptic density (Figure 2) [90].
4.2 D-serine
D-serine is a potential co-agonist at NMDA receptor which is a possible  
biomarker in depression. Numerous studies highlighted the abnormality of 
D-serine levels in depression highlighting the antidepressant properties of  
D-serine [91–95]. Ketamine was found to inhibitor the transport of D-serine while 
ketamine metabolites were observed to decrease intracellular (PC-12 cells) con-
centrations of D-serine thus increasing plasma D-serine levels which is possible 
prediction related to its to antidepressant action [96–99].
4.3 Opioid system
Ketamine also have capability to bind with opioid receptors (mu, delta 
and kappa), monoaminergic receptors and transporters, and muscarinic and 
Figure 2. 
Flow diagram of antidepressant activity of ketamine. (1) ketamine binds with N-methyl-d-aspartate receptors 
(NMDARs) and reduce excitability of γ-aminobutyric acid (GABA) ergic interneurons that results, (2) non-
inhibition of glutamatergic neurons, (3) that further increase glutamate release which binds with α-amino-3-
hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors resulting inflow of sodium and calcium into 
cell, (4) cause activation of voltage gated calcium channels, (5) that further triggers the release of brain-derived 
neurotrophic factor (BDNF) into glutamate synapse. (6) BDNF from synapse binds with tropomyosin receptor 
kinase B (TrkB) resulting activation of MEK–ERK and PI3K-Akt signaling cascades that converge on to 
mTOR lead to (7) increased synaptic protein translation. (8) increased proteins in synapse lead to increased 
AMPAR-mediated synaptic transmission causing elevated synaptogenesis. All these events are hypothesized to 
restore disrupted connectivity between key brain regions and can be the possible reason of rapid and sustained 
antidepressant action of ketamine.
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nicotinic cholinergic receptors [100]. Proposition is made that anti-suicidal as 
well as antidepressant actions of ketamine is related to the opioid system which is 
confirmed from the pre-treatment of naltrexone after that antidepressant effect 
was attenuated in patients [100, 101]. However many discrepancies are also exist 
along with [102, 103] because buprenorphine and methadone both are agonists 
to the opioid receptors and does not have any effect on antidepressant properties 
of ketamine [103]. These results rebels the role of opioid system in ketamine’s 
antidepressant effects. Thus role of opioid in ketamine’s antidepressant effects is 
yet unclear and controversial.
5. Future trends
With unique mechanism of action as compared to traditional antidepressants 
along with anti-suicidal properties, ketamine successfully attracted the research-
ers and physiologists toward itself in last two decades. However large mechanism 
of actions are still need to uncover thus it will be continue to be a hot topic 
and active area of research in psychiatry. There if a dire need to investigate the 
appropriate safety to efficacy ration of ketamine in depression therapy along with 
establishment of appropriate regimens for maintenance of therapy and discon-
tinuation too. Reliable biomarkers are also needed to properly predict the response 
and adverse effects of ketamine. Numerous reports are also present in literature 
that caution the utilization of ketamine as an antidepressant in clinical practice 
[76, 104–108]. Keeping these thing apart, currently ketamine is emerging as a 
promising approach for treatment of patients suffering from TRD. Ketamine and 
its related neurochemical biomarkers can act as leads for development of future 
antidepressants.
6. Conclusion
Rapid antidepressant effect of ketamine depression therapy and important 
discovery in depression research. Its efficacy against TRD and anti-suicidal poten-
tial is a boon in depression research but at the same time its negative side effects 
and potential for being abuse is not to be neglected. However pathways like BDNF, 
mTOR, AMPA along D-serine and opioid receptors provided sufficient understand-
ing but large portion of its mechanisms are still need to uncover. Even some studies 
create conflict to each other which is needed to be resolved. Overall analysis suggest 
that there is an important need to discover all aspects of ketamine in depres-
sion therapy to efficient use of this drug as an antidepressant in clinical practice. 
Moreover, ketamine can act as a lead for the development of new class of rapidly 
acting future antidepressant agents.
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